论文部分内容阅读
为探讨静脉溶栓治疗急性心肌梗塞的疗效，用蝮蛇抗栓酶（ＶＡＥ）、小剂量尿激酶（ＬＵＫ）、大剂量尿激酶（ＨＵＫ）静脉注射治疗急性心肌梗塞各５１例、３３例及５１例进行疗效比较。冠脉再通率分别为３９．２２％（２０／５１）、４５．４５％（１５／３３）与６０．０８％（３１／５１）（每两组相比Ｐ均＜０．０１）；５周病死率分别为９．８０％（５／５１）、９．０９％（３／３３）与７．８４％（４／５１）（Ｐ＜０．０１）；出血率分别为１３．７２％（７／５１）、１２．１２％（４／３３）与１３．７２％（７／５１）（Ｐ＞０．０５）；ＱＲＳ记分分别为３．１２±０．４２、２．９８±０．４０与２．７９±０．３９；ＣＫ峰值分别为２４８．７３±３１．２２Ｕ、２１６．６±２５．６７Ｕ与２１９．６８±２３．１６Ｕ。ＨＵＫ组疗效明显优于ＶＡＥ和ＬＵＫ组。推荐ＵＫ的适宜用量为１５０万Ｕ３０分钟内静脉滴入。
To investigate the curative effect of intravenous thrombolysis on acute myocardial infarction, 51 cases of acute myocardial infarction (MI), 33 cases of acute myocardial infarction (AMI) were treated with intravenous injection of high dose urokinase (HUK) 51 cases were compared. The rates of coronary recanalization were 39.22% (20/51), 45.45% (15/33) and 60.08% (31/51) respectively (P <0.01 for each group). The 5-week mortality rates were 9.80% (5/51), 9.09% (3/33) and 7.84% (4/51) respectively (P <0.01). The bleeding rates were 13.72 (7/51), 12.12% (4/33) and 13.72% (7/51) respectively (P> 0.05). The QRS scores were 3.12 ± 0.42 and 2.98 ± 0.40 and 2.79 ± 0.39 respectively; CK peaks were 248.73 ± 31.22U, 216.6 ± 25.67U and 219.68 ± 23.16U, respectively. HUK group was significantly better than VAE and LUK group. Recommended the appropriate amount of UK 1.5 million U30 intravenous infusion within 30 minutes.